phrykt

Alumis Inc. (ALMS): who owns it and who trades it

As of Nov 16, 2026, ALMS insiders reported 15 open-market sales worth $1.6M and 24 purchases worth $36.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Srinivas Akkaraju (Director), with $1M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Alumis

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALMS

199 funds and institutions reported ALMS shares worth $3.4B at the end of Q2 2026. The largest holder is AyurMaya Capital Management Company, LP with $426M.

10 largest owners, by value

AyurMaya Capital Management Company, LP$426M
BlackRock, Inc.$231M
FMR LLC (Fidelity)$190M
Deep Track Capital, LP$179M
Samsara Biocapital, LLC$179M
Foresite Capital Management V, LLC$166M
T. Rowe Price Associates$146M
VenBio Partners LLC$127M
Foresite Capital Management VI LLC$120M
Vanguard Capital Management LLC$119M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
AyurMaya Capital Management Company, LP15.14M–$426M–
BlackRock, Inc.8.22M–$231M+15%
FMR LLC (Fidelity)6.77M–$190M+595%
Deep Track Capital, LP6.35M–$179M-6%
Samsara Biocapital, LLC6.35M–$179MNo change
Foresite Capital Management V, LLC5.90M–$166MNo change
T. Rowe Price Associates5.20M–$146M+58%
VenBio Partners LLC4.53M–$127MNo change
Foresite Capital Management VI LLC4.25M–$120MNo change
Vanguard Capital Management LLC4.22M–$119M+5%
Nextech Invest Ltd.3.54M–$99.6MNo change
Cormorant Asset Management, LP3.29M–$92.5M-17%
Saturn V Capital Management LP2.92M–$82M-9%
Octagon Capital Advisors LP2.83M–$79.7MNo change
Jupiter Topco LLC2.36M–$66.2M–
California State Teachers Retirement System2.22M–$78.8M+2643%
State Street Corp2.19M–$61.5M+21%
Geode Capital Management, LLC2.17M–$61M+13%
Mpm Bioimpact LLC2.02M–$56.8M-15%
Baker Bros. Advisors LP2.01M–$56.6MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ALMS insiders reported $36.5M of open-market purchases and $1.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$36.5M
24 trades, 4 people
Sales, 12 months
$1.6M
15 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 4, 2026

Purchases and sales by month

$17M$17MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Roy C. HardimanChief Business & StrategSale652$6.52$4.3KForm 4
Nov 2, 2026John R. SchroerCFOSale794$6.52$5.2KForm 4
Nov 2, 2026David M GoldsteinChief Scientific OfficerSale629$6.52$4.1KForm 4
Nov 2, 2026Jorn DrappaChief Medical OfficerSale593$6.52$3.9KForm 4
Nov 2, 2026Mark Christopher BradleyChief Development OfficeSale623$6.52$4.1KForm 4
Nov 2, 2026Sanam PangaliChief Legal OfficerSale332$6.52$2.2KForm 4
Sep 8, 2026Srinivas AkkarajuDirectorSale48,066$10.55$507KForm 4
Sep 8, 2026Srinivas AkkarajuDirectorPurchase273,291$10.63$2.9MForm 4
Sep 8, 2026Srinivas AkkarajuDirectorPurchase273,290$10.63$2.9MForm 4
Sep 8, 2026Srinivas AkkarajuDirectorSale48,065$10.55$507KForm 4
Sep 4, 2026Srinivas AkkarajuDirectorPurchase220,070$11.17$2.5MForm 4
Aug 3, 2026John R. SchroerCFOSale3,282$26.37$86.5KForm 4
Aug 3, 2026Sanam PangaliChief Legal OfficerSale1,364$26.37$36KForm 4
Aug 3, 2026Roy C. HardimanChief Business & StrategSale2,692$26.37$71KForm 4
Aug 3, 2026David M GoldsteinChief Scientific OfficerSale2,596$26.37$68.5KForm 4
Aug 3, 2026Jorn DrappaChief Medical OfficerSale2,447$26.37$64.5KForm 4
Aug 3, 2026Mark Christopher BradleyChief Development OfficeSale2,572$26.37$67.8KForm 4
Jul 6, 2026Sanam PangaliChief Legal OfficerSale5,000$28.00$140KForm 4
Jan 9, 2026Srinivas AkkarajuDirectorPurchase588,235$17.00$10MForm 4
Jan 8, 2026Foresite Labs, LLC +110% ownerPurchase117,647$17.00$2MForm 4
Jan 8, 2026Foresite Labs, LLC +110% ownerPurchase294,117$17.00$5MForm 4
Dec 5, 2025Srinivas AkkarajuDirectorPurchase70,028$10.01$701KForm 4
Dec 5, 2025Srinivas AkkarajuDirectorPurchase51,380$10.73$551KForm 4
Dec 5, 2025Srinivas AkkarajuDirectorPurchase64,969$8.95$581KForm 4
Dec 4, 2025Srinivas AkkarajuDirectorPurchase66,027$8.18$540KForm 4
Dec 3, 2025Srinivas AkkarajuDirectorPurchase100,000$7.75$775KForm 4
Dec 2, 2025Srinivas AkkarajuDirectorPurchase96,000$7.55$725KForm 4
Dec 1, 2025Srinivas AkkarajuDirectorPurchase86,350$7.46$644KForm 4
Nov 28, 2025Srinivas AkkarajuDirectorPurchase38,702$7.64$296KForm 4
Nov 26, 2025Srinivas AkkarajuDirectorPurchase48,537$7.64$371KForm 4
Nov 21, 2025Foresite Labs Fund I, L.P. +810% ownerPurchase72,212$7.38$533KForm 4
Nov 20, 2025Srinivas AkkarajuDirectorPurchase125,743$7.20$905KForm 4
Nov 19, 2025Foresite Labs Affiliates 2021, LLC +110% ownerPurchase190,500$6.56$1.2MForm 4
Nov 19, 2025Srinivas AkkarajuDirectorPurchase137,772$6.56$904KForm 4
Nov 18, 2025Foresite Labs Affiliates 2021, LLC +110% ownerPurchase117,374$6.19$727KForm 4
Nov 18, 2025Srinivas AkkarajuDirectorPurchase102,652$6.05$621KForm 4
Nov 17, 2025Foresite Labs Affiliates 2021, LLC +110% ownerPurchase50,000$5.60$280KForm 4
Nov 17, 2025Foresite Labs Affiliates 2021, LLC +110% ownerPurchase150,000$5.59$838KForm 4
Nov 17, 2025Srinivas AkkarajuDirectorPurchase914$5.51$5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Srinivas AkkarajuDirector$25.9M$1MSep 8, 2026
Foresite Labs, LLC10% owner$7M–Jan 8, 2026
Foresite Labs Affiliates 2021, LLC10% owner$3.1M–Nov 19, 2025
Foresite Labs Fund I, L.P.10% owner$533K–Nov 21, 2025
Sanam PangaliChief Legal Officer–$178KNov 2, 2026
John R. SchroerChief Financial Officer–$91.7KNov 2, 2026
Roy C. HardimanChief Business & Strategy Ofcr–$75.2KNov 2, 2026
David M GoldsteinChief Scientific Officer–$72.6KNov 2, 2026
Mark Christopher BradleyChief Development Officer–$71.9KNov 2, 2026
Jorn DrappaChief Medical Officer–$68.4KNov 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALMS short interest

11.03M ALMS shares are sold short. Over the last 12 reports the number of shares short went down 3%.

As of Oct 30, 2026, 11.03M ALMS shares were sold short, down 0.4% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.8 trading days (days to cover).

Shares short

11.03MMay 15Oct 3015.59M

Days to cover

5.8May 15Oct 3016.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.03M–-0%1.91M5.8
Oct 15, 202611.08M–+8%2.28M4.9
Sep 30, 202610.30M–+63%2.87M3.6
Sep 15, 20266.30M–+12%7.18M1.0
Aug 31, 20265.65M–-4%798,9567.1
Aug 14, 20265.85M–+2%897,5576.5
Jul 31, 20265.77M–-15%943,0996.1
Jul 15, 20266.76M–-53%1.77M3.8
Jun 30, 202614.29M–+13%1.89M7.6
Jun 15, 202612.66M–+14%1.45M8.7
May 29, 202611.07M–-3%853,93813.0
May 15, 202611.36M–+1%806,69114.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Alumis company events

Alumis filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Sep 1, 2026.

  1. Sep 1, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results on September 1, 2026. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Aug 10, 2026AnnouncementAlumis Inc. issued a press release titled “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies”. Filing
  4. Jul 2, 2026VoteReported shareholder vote results. Filing
  5. Jun 29, 2026AnnouncementAlumis Inc. updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
  6. May 14, 2026ResultsReleased financial results. Filing
  7. Mar 30, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis”. Filing
  8. Mar 19, 2026ResultsReleased financial results. Filing
  9. Jan 9, 2026AnnouncementThe Company entered into an underwriting agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 17,650,000 shares of the Company’s voting… Filing
  10. Jan 6, 2026AnnouncementAlumis Inc. issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program”. Filing
  11. Jan 2, 2026AnnouncementAlumis Inc. and its wholly-owned subsidiary Acelyrin, Inc. issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb Bio, Inc., after Climb Bio knowingly and willfully refused to pay a $3 million Development Milestone payment due January 1, 2026 under the Asset… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Alumis financials

Famous investors that hold ALMS

3 of the 50 well-known investors we track reported holding ALMS in their latest 13F filing. The largest position is Israel Englander's, worth $24.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.33M$24.6M0.0%+405%
Ken Griffin · Citadel AdvisorsQ3 20262.39M$17.6M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202664,492$477K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ALMS in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A0.0%
Nov 5, 2026FMR LLC13G/A0.0%

Questions about Alumis Inc. (ALMS) stock

Who owns the most ALMS stock?

The largest reported owner of Alumis Inc. (ALMS) is AyurMaya Capital Management Company, LP. In total, 199 funds and institutions reported holding ALMS at the end of Q2 2026. See the largest owners.

Are ALMS insiders buying or selling?

In the last 12 months, ALMS insiders reported 24 open-market purchases worth $36.5M and 15 sales worth $1.6M. The latest trade was on Nov 2, 2026. See every trade.

What is the short interest in ALMS?

As of Oct 30, 2026, 11.03M ALMS shares were sold short, down 0.4% from the report before. At the average daily volume of 1.91M shares, buying them all back would take about 5.8 trading days (days to cover). See the history.

Which famous investors hold ALMS?

3 of the 50 well-known investors we track reported ALMS in their latest 13F filing, including Israel Englander, Ken Griffin, Paul Tudor Jones. The largest position is worth $24.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.